Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Gets FDA OK for New Version of CYP2D6 Kit

NEW YORK (GenomeWeb News) – Luminex announced after the close of the market Monday that the US Food and Drug Administration has cleared for marketing a new version of its xTAG CYP2D6 kit.

The test identifies variations in the Cytochrome P450 2D6 gene, which can affect how a patient metabolizes certain drugs. According to Luminex, CYP2D6 metabolizes more than 25 percent of drugs on the market today, including cardiovascular drugs, anti-psychotics, anti-depressants, and pain medications, among others.

Luminex said the new version of the test, which also has received the CE Mark, optimizes the performance on the *17 allele and features an updated software algorithm that detects all 17 genotypes for which the assay is cleared.

In addition to clearance of the new CYP2D6 test, Luminex said that it has submitted to the FDA and European regulators applications for clearance of its xTAG CYP2C19 kit, another drug metabolism assay. The CYP2C19 enzyme is responsible for metabolizing a variety of prodrugs and drugs used to treat ulcers, seizures, malaria, and anxiety, and plays a role in metabolizing beta blockers and some antidepressants, said Luminex.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.